Zomedica Pharmaceuticals Corp. Common Shares (ZOM): Price and Financial Metrics


Zomedica Pharmaceuticals Corp. Common Shares (ZOM)

Today's Latest Price: $0.16 USD

0.00 (-0.99%)

Updated Jun 2 10:01am

Add ZOM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ZOM Daily Price Range
ZOM 52-Week Price Range

ZOM Stock Price Chart More Charts


ZOM Price/Volume Stats

Current price $0.16 52-week high $0.50
Prev. close $0.16 52-week low $0.11
Day low $0.16 Volume 7,229,042
Day high $0.17 Avg. volume 19,442,432
50-day MA $0.18 Dividend yield N/A
200-day MA $0.28 Market Cap 17.31M

Zomedica Pharmaceuticals Corp. Common Shares (ZOM) Company Bio


Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.


ZOM Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ZOM Latest Social Stream


Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about Zomedica Pharmaceuticals Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Zomedica Pharmaceuticals Corp. Closes $20 Million Public Offering

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. The gross proceeds from this offering are approximately $20.0 million, before deducting placement agent’s fees and other estimated offering expenses payable by the Company, assuming none of the warrants sold in this offering are exercised for cash.

Yahoo | May 29, 2020

Zomedica Pharmaceuticals Corp. Announces $20 Million Public Offering

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.15 per common share.

Yahoo | May 27, 2020

Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic Platform

Zomedica (NYSE American: ZOM), a veterinary diagnostic company, announced today that it has completed the final verification of three additional assays for use with its TRUFORMA™ point-of-care diagnostic platform. The newly verified assays, feline total T4 (“tT4”), and canine and feline TSH (thyroid stimulating hormone), together with the previously verified canine total tT4 assay, represent completion of the first two assays for both canine and feline of the total of five assays initially planned for use with the TRUFORMA™ platform. The TRUFORMA™ diagnostic device, which is smaller than a desktop printer, has been designed to provide highly sensitive, species-optimized initial assays for the diagnosis of thyroid disease in dogs and cats, and adrenal disease in dogs.

Yahoo | May 20, 2020

Zomedica Pharmaceuticals Corp (ZOM) Reports Q1 Loss, Lags Revenue Estimates

Zomedica Pharmaceuticals Corp (ZOM) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 11, 2020

Zomedica Announces First Quarter 2020 Financial Results

Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic company, today reported consolidated financial results for the first quarter ended March 31, 2020. The COVID-19 pandemic has impacted our expected timing for the completion of the development.

Yahoo | May 11, 2020

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo -9.04%
3-mo -38.46%
6-mo -54.29%
1-year -45.52%
3-year -91.41%
5-year N/A
YTD -51.66%
2019 -73.09%
2018 -37.88%
2017 91.99%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7684 seconds.